Primary Myelofibrosis (PMF) Clinical Trial
Official title:
A Phase 2, Open-label, Translational Biology Study of Momelotinib in Transfusion-Dependent Subjects With Primary Myelofibrosis (PMF) or Post-polycythemia Vera or Post-essential Thrombocythemia Myelofibrosis (Post-PV/ET MF)
This study will evaluate the transfusion independence response rate in transfusion-dependent adults with myelofibrosis after treatment with momelotinib (MMB).
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Active, not recruiting |
NCT03441113 -
Extended Access of Momelotinib in Adults With Myelofibrosis
|
Phase 2 | |
| Completed |
NCT01558739 -
Exploratory Phase II Study of INC424 Patients With Primary Myelofibrosis (PMF) or Post Polycythaemia Myelofibrosis (PPV MF) or Post Essential Thrombocythaemia Myelofibrosis (PET-MF)
|
Phase 4 | |
| Completed |
NCT00910728 -
Study to Assess the Safety of AZD1480 in Patients With Myeloproliferative Diseases
|
Phase 1 | |
| Completed |
NCT02101268 -
Efficacy of Momelotinib Versus Best Available Therapy in Anemic or Thrombocytopenic Subjects With Primary Myelofibrosis (MF), Post-polycythemia Vera MF, or Post-essential Thrombocythemia MF
|
Phase 3 | |
| Completed |
NCT03136185 -
Bomedemstat (IMG-7289/MK-3543) in Participants With Myelofibrosis (IMG-7289-CTP-102/MK-3543-002)
|
Phase 1/Phase 2 | |
| Completed |
NCT04217993 -
Jaktinib for the Treatment of Ruxolitinib Intolerance of Myelofibrosis
|
Phase 2 | |
| Recruiting |
NCT03662126 -
KRT-232 Versus Best Available Therapy for the Treatment of Subjects With Myelofibrosis Who Are Relapsed or Refractory to JAK Inhibitor Treatment
|
Phase 2/Phase 3 | |
| Terminated |
NCT03935555 -
Assess the Safety, Tolerability Oral PU-H71 in Subjects Taking Ruxolitinib
|
Phase 1 | |
| Recruiting |
NCT04878003 -
Study of KRT-232 or TL-895 in Janus Associated Kinase Inhibitor Treatment-Naïve Myelofibrosis
|
Phase 2 | |
| Available |
NCT04745637 -
Managed Access Programs for INC424, Ruxolitinib
|